Lv3
315 积分 2021-03-16 加入
[Consensus on the molecular residual disease testing in solid tumor]
17天前
已完结
Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy
20天前
已完结
The 1+Million Genomes Minimal Dataset for Cancer
26天前
已完结
Variant allele frequency: a decision-making tool in precision oncology?
1个月前
已完结
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance
1个月前
已完结
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
1个月前
已完结
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
1个月前
已完结
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group
1个月前
已完结
Guidance for estimating penetrance of monogenic disease-causing variants in population cohorts
1个月前
已完结
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group
1个月前
已完结
皖公网安备34019202002308
